We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    • European Medicines Agency

    Health

    EMA Recommends Valneva’s Chikungunya Vaccine for Use in Europe

    The European Medicines Agency (EMA) has recommended Valneva’s single-dose chikungunya vaccine, Ixchiq, as the first preventive shot against the disease in Europe. With no approved drugs for chikungunya, the vaccine’s approval could be crucial in combating its spread in the region, especially with the increasing risks associated with climate change and global travel.

    Posted on Jhon
    Health

    MHRA updates on study of risks associated with children born to men taking valproate

    The Medicines and Healthcare products Regulatory Agency (MHRA) has provided an update on a new study regarding the risks associated with children born to men taking valproate. The new safety measures introduced in the UK are applicable to both male…

    Posted on Jhon